Marta Araujo-Castro1, Héctor Pian2, Ignacio Ruz-Caracuel2, Alberto Acitores Cancela3, Eider Pascual-Corrales1, Víctor Rodríguez Berrocal3,4. 1. Neuroendocrinology Unit, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Instituto de Investigación Biomédica Ramón y Cajal, Madrid, Spain. 2. Endocrinology Unit, Department of Pathology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 3. Neuroendocrinology Unit, Department of Neurosurgery, Hospital Universitario Ramón y Cajal, Madrid, Spain. 4. Endoscopic Skull Base Unit, Department of Neurosurgery, Hospital Universitario HM Puerta del Sur, Madrid, Spain.
Abstract
PURPOSE: To evaluate whether presurgical treatment using long-acting somatostatin receptor ligands (SRL) may change pituitary tumor consistency and improve surgical outcome in GH-secreting pituitary macroadenomas. METHODS: Retrospective study of 40 patients with GH-secreting pituitary macroadenomas operated for the first time by endoscopic transsphenoidal approach. Tumor consistency was evaluated intraoperatively and then correlated with histopathological fibrosis parameters and surgical outcomes. Surgical remission was reported based on the 2010 criteria. RESULTS: The mean tumor size of GH-secreting macroadenomas was of 16.9 ± 8.2 mm and 25 were invasive pituitary adenomas (PAs). Presurgical treatment with long-acting SRL was performed in 17 patients (11 lanreotide, 6 octreotide). The cure rate was higher in those patients pre-treated with monthly doses ≥30 mg of octreotide or ≥90 mg of lanreotide than in those treated with lower doses or untreated (8/11 (72.7%) vs 11/29 (37.9%), P = 0.049). However, although the proportion of soft tumors increased as higher doses of SRL were considered in the pre-treated group, no statistical significance was reached, even when the highest approved monthly doses were used (6/6 (100%) vs 23/34 (67.7%), P = 0.102). Moreover, we found that the remission rate was similar between fibrous and soft tumors (P = 0.873) and also of surgical complications (P = 0.859), despite of the higher prevalence of Knosp >2 (P = 0.035) and very large PA (P = 0.025) in fibrous tumors than in soft tumors. CONCLUSIONS: Although presurgical treatment with high doses of SRL was associated with a 2.2-fold greater chance of surgical remission, this benefit was not related with changes in tumor consistency induced by the presurgical treatment.
PURPOSE: To evaluate whether presurgical treatment using long-acting somatostatin receptor ligands (SRL) may change pituitary tumor consistency and improve surgical outcome in GH-secreting pituitary macroadenomas. METHODS: Retrospective study of 40 patients with GH-secreting pituitary macroadenomas operated for the first time by endoscopic transsphenoidal approach. Tumor consistency was evaluated intraoperatively and then correlated with histopathological fibrosis parameters and surgical outcomes. Surgical remission was reported based on the 2010 criteria. RESULTS: The mean tumor size of GH-secreting macroadenomas was of 16.9 ± 8.2 mm and 25 were invasive pituitary adenomas (PAs). Presurgical treatment with long-acting SRL was performed in 17 patients (11 lanreotide, 6 octreotide). The cure rate was higher in those patients pre-treated with monthly doses ≥30 mg of octreotide or ≥90 mg of lanreotide than in those treated with lower doses or untreated (8/11 (72.7%) vs 11/29 (37.9%), P = 0.049). However, although the proportion of soft tumors increased as higher doses of SRL were considered in the pre-treated group, no statistical significance was reached, even when the highest approved monthly doses were used (6/6 (100%) vs 23/34 (67.7%), P = 0.102). Moreover, we found that the remission rate was similar between fibrous and soft tumors (P = 0.873) and also of surgical complications (P = 0.859), despite of the higher prevalence of Knosp >2 (P = 0.035) and very large PA (P = 0.025) in fibrous tumors than in soft tumors. CONCLUSIONS: Although presurgical treatment with high doses of SRL was associated with a 2.2-fold greater chance of surgical remission, this benefit was not related with changes in tumor consistency induced by the presurgical treatment.
Authors: G Zieliński; J K Podgórski; A Koziarski; J Siwik; W Zgliczyński; W Wieliczko Journal: Neurol Neurochir Pol Date: 2001 Mar-Apr Impact factor: 1.621
Authors: Hai Sun; Jessica Brzana; Chris G Yedinak; Sakir H Gultekin; Johnny B Delashaw; Maria Fleseriu Journal: J Neurol Surg B Skull Base Date: 2013-09-09
Authors: Philippe J Caron; John S Bevan; Stephan Petersenn; Daniel Flanagan; Antoine Tabarin; Gaëtan Prévost; Pascal Maisonobe; Antoine Clermont Journal: J Clin Endocrinol Metab Date: 2013-01-01 Impact factor: 5.958
Authors: David Netuka; André Grotenhuis; Nicolas Foroglou; Francesco Zenga; Sebastien Froehlich; Florian Ringel; Nicolas Sampron; Nick Thomas; Martin Komarc; Mikuláš Kosák; Martin Májovský Journal: Sci Rep Date: 2022-04-20 Impact factor: 4.996